Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial

BACKGROUND: Treatment of breast cancer with aromatase inhibitors is associated with damage to bones. NCIC CTG MA.27 was an open-label, phase 3, randomised controlled trial in which women with breast cancer were assigned to one of two adjuvant oral aromatase inhibitors—exemestane or anastrozole. We p...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Oncol
Autori principali: Goss, Paul E, Hershman, Dawn L, Cheung, Angela M, Ingle, James N, Khosla, Sundeep, Stearns, Vered, Chalchal, Haji, Rowland, Kendrith, Muss, Hyman B, Linden, Hannah M, Scher, Judite, Pritchard, Kathleen I, Elliott, Catherine R, Badovinac-Crnjevic, Tanja, St Louis, Jessica, Chapman, Judith-Anne W, Shepherd, Lois E
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4352316/
https://ncbi.nlm.nih.gov/pubmed/24636210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70035-X
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi